by We thus quantified neurosteroid levels in serum samples from men and women who served in the U.S. approach, the imaging genetics methods repertoire has recently been extended to include more complex strategies to aid the hypothesis-free identification of variants, genes, Lox and pathways associated with these risk-related neuroimaging phenotypes. Methods:In a series of studies in healthy individuals and unaffected first-degree relatives of schizophrenia patients we have established and confirmed the link of these phenotypes to the genetic liability for schizophrenia. We have further explored the genetic contributions to these phenotypes using a broader array of imaging genetics methods including single-variant approaches exploring the effects of candidate genes and genome-wide supported psychosis risk variants. Recently, we Astemizole have utilized more complex strategies in order to examine numerous genetic variants simultaneously using reliability-optimized neuroimaging risk phenotypes, gene fine mapping approaches, and gene set enrichment analyses. Results:For DLPFC – hippocampus functional connectivity our analyses replicate prior associations of this phenotype with the genetic risk for the illness, highlight associations with genetic loci supported by prior meta-analysis Astemizole and genome-wide association studies (e.g., NRG1, ZNF804A, CACNAB2, extended MHC genomic region), and provide evidence for the role of genes and biological pathways involved in neurodevelopmental and plasticity processes. For ventral striatal activation during reward processing our data provide the first evidence for a systems-level intermediate phenotype signaling increased genetic risk for schizophrenia, which demonstrates association with a genome-wide supported psychosis risk variant in ITIH3/4 as well as the enrichment of gene sets and pathways involved in dopamine neurotransmission. Conclusions:Our findings support the utility of fMRI-based neuroimaging phenotypes for the examination of genes and pathways associated with an increased genetic liability for schizophrenia. They further underscore the value of different imaging genetics analysis strategies, the reliability-based definition of neuroimaging risk phenotypes, the independent replication of findings, and the use of comparable data processing methods and analysis strategies across centers. Disclosure:Nothing to Disclose. == 1.2 Impact of Highly Deleterious Functional Genetic Variants on Subcortical Brain Volume == == David Glahn == == Yale University, Hartford, Connecticut == Background:There is growing evidence that the same genetic factors that influence brain structure and function also confer risk for child- or adolescent onset mental illnesses like schizophrenia, bipolar disorder, major depression and autism. If so, genes associated with neuroanatomic variation in healthy populations are reasonable candidate genes for mental illnesses. Subcortical brain regions act jointly with cortical areas to coordinate movement, learning and memory, emotional responses and reinforcement and have been shown to be sensitive to genetic liability to a host of mental illnesses. Recently, the ENIGMA2 consortium used genome-wide association to search for genetic loci influencing subcortical regions in over 29,000 subjects, reporting a number of genome wide significant SNPs for the putamen, caudate nucleus, and hippocampal volume. While this effort represents a major advance for imaging Astemizole genomics research, the common variants localized in this study are not explicitly functional and thus do not directly point to specific genes. Like most GWAS studies, localized SNPs show loci of variable size depending on local linkage disequilibrium and follow-up studies are needed to definitively determine genes. In addition to common variants, rare variants derived from either whole genome or exome sequencing appear to play a roll in risk for mental illness and in neuroanatomic variance. Identification of a rare practical variant with a large absolute effect size, though present in a handful of affected individuals, can be adequate to verify that a given gene is involved in trait variance. However, tens of millions of potential variants are provided in whole genome sequencing studies and methods for controlling statistical bias resulting from performing that many statistical tests are often prohibitive. One approach is to use bioinformatic data to select nonsynonymous variants shown to be highly deleterious for protein manifestation a priori. This approach dramatically reduces the number of variants tested and provides strong evidence that a specific gene influences the selected trait. Methods:Here, we examined the association between 1981 rare highly deleterious nonsynonymous (HD-NS) variants and subcortical mind quantities parcellated with FreeSurfer in over 800 Mexican-American from randomly selected prolonged pedigrees. Results:Six HD-NS variants in six independent genes were recognized influencing bilateral putamen (MOG gene, p=6.27×10-6; Astemizole SCN10A gene, p=2.50×10-5), pallidum (OR5AR1 gene, p=1.50×10-5, SERPINA3 gene, p=2.60×10-5), and caudate (CEP128 gene, p=3.30×10-5, CEP55 gene, p=3.70×10-5) volumes. Of these,.
